Vaccine Breakthrough Infections with SARS-CoV-2 Variants

New England Journal of Medicine.  April 21, 2021

List of authors.

  • Ezgi Hacisuleyman, Ph.D.,
  • Caryn Hale, Ph.D.,
  • Yuhki Saito, Ph.D.,
  • Nathalie E. Blachere, Ph.D.,
  • Marissa Bergh, B.S.N.,
  • Erin G. Conlon, Ph.D.,
  • Dennis J. Schaefer-Babajew, Ph.D.,
  • Justin DaSilva, M.S.,
  • Frauke Muecksch, Ph.D.,
  • Christian Gaebler, M.D.,
  • Richard Lifton, M.D., Ph.D.,
  • Michel C. Nussenzweig, M.D., Ph.D.,
  • Theodora Hatziioannou, Ph.D.,
  • Paul D. Bieniasz, Ph.D.,
  • and Robert B. Darnell, M.D., Ph.D.

Abstract: Emerging variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are of clinical concern. In a cohort of 417 persons who had received the second dose of BNT162b2 (Pfizer–BioNTech) or mRNA-1273 (Moderna) vaccine at least 2 weeks previously, we identified 2 women with vaccine breakthrough infection. Despite evidence of vaccine efficacy in both women, symptoms of coronavirus disease 2019 developed, and they tested positive for SARS-CoV-2 by polymerase-chain-reaction testing. Viral sequencing revealed variants of likely clinical importance, including E484K in 1 woman and three mutations (T95I, del142–144, and D614G) in both. These observations indicate a potential risk of illness after successful vaccination and subsequent infection with variant virus, and they provide support for continued efforts to prevent and diagnose infection and to characterize variants in vaccinated persons. (Funded by the National Institutes of Health and others.)

In case you missed it, Dr. Geert Vanden Bossche spoke about this:

About budbromley

Bud is a retired life sciences executive. Bud's entrepreneurial leadership exceeded three decades. He was the senior business development, marketing and sales executive at four public corporations, each company a supplier of analytical and life sciences instrumentation, software, consumables and service. Prior to those positions, his 19 year career in Hewlett-Packard Company's Analytical Products Group included worldwide sales and marketing responsibility for Bioscience Products, Global Accounts and the International Olympic Committee, as well as international management assignments based in Japan and Latin America. Bud has visited and worked in more than 65 countries and lived and worked in 3 countries.
This entry was posted in Uncategorized. Bookmark the permalink.

1 Response to Vaccine Breakthrough Infections with SARS-CoV-2 Variants

  1. budbromley says:

    Bob, if you find articles explaining immune escape, please post them. Public needs to know.

    Get Outlook for Android



Leave a Reply

Please log in using one of these methods to post your comment: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.